Replies to post #173727 on Avid Bioservices Inc (CDMO)

[biopharm]

Hakan Mellstedt : Peregrine Pharmaceuticals KOL :

Hakan is one KOL that I keep trying to figure out what his role will be...

not sure if this is new but definitely don't remember seeing this before, as scientific advisor of Korea Stem Cell Bank as it just popped up today on a google search... so its possible?? they just updated his profile on this link below.

Dr. Hakan Mellstedt, MD, PhD serves as Scientific Advisor of Korea Stem Cell Bank Co., Ltd. Dr. Mellstedt is a Professor of Oncologic Biotherapy at the Karolinska Institute and Managing Director of Cancer Center Karolinska, Karolinska Institute, Stockholm, Sweden. He serves as Chief Physician at the Department of Oncology & Haematology, Karolinska Hospital, Stockholm, and has specialist certificates in Oncology, Hematology and Internal Medicine. He served as a Scientific Advisor of Micromet, Inc. (also known as Micromet Ag). Dr. Mellstedt served as Head of the Division of Experimental Oncology, Uppsala University from 1996 to 1999. He was Editor-in-Chief, Review Series ONCOLOGY since 1996, and served on the editor board of many important journals related to the cancer field. He serves as Chairman and Member of clinical trial advisory board of Oxigene Inc. He served as Chairman, Swedish Society of Oncology from 1993 to 1999. Dr. Mellstedt serves as a Member of Medical Advisory Board at KAEL-GemVax Co., Ltd. Dr. Mellstedt serves as a Member of Advisory Board of Gemvax As. Dr. Mellstedt serves Chairman and President of ESMO (European Society for Medical Oncology). He serves as a Director of Kancera AB. He served as a Member of the Medical Advisory Board at Wilex AG. He served as a Member of Scientific Advisory Board of Affibody Holding AB (also known as Affibody AB). He published more than 450 articles in the areas of hematology, Contributions to Biomolecular Technologies. His Scientific prizes are : Alfaferone 1989 Prize(Italian Institute of Immunology) and Jan Waldenström Award , VIIIth International Myeloma Workshop, 2001. Dr. Mellstedt received M.D and Ph.D at Karolinska Institute, Stockholm, Sweden.

http://investing.businessweek.com/research/stocks/private/person.asp?personId=21875542&privcapId=47790443&previousCapId=117152678&previousTitle=KANCERA%20AB

----------------------------------------------------------

Hakan
Mellstedt

Scientific
Advisor

- Professor of Oncologic Biotherapy at the Karolinska Institute
- Managing Director of CancerCentreKarolinska (CCK) at the Karolinska University Hospital in Stockholm, Sweden
- Chief Physician in the Departments of Oncology and Haematology
- Chairman of the Swedish Society of Oncology
- Chairman of the ESMO Foundation
- Past President of ESMO
- President of ESMO
- M.D/Ph.D at Karolinska Institute, Stockholm, Sweden

http://kscb.co.kr/cell/eng/company/company4.php?PHPSESSID=e97f422a2166c2648c1ccb5aa3fe0e62

[biopharm]

To just keep track of Hakan's numbers on research gate as of April 21, 2014

Following: 23

Followers: 64

Looks like a KOL to Peregrine Pharmaceuticals has lots of others interested in what Hakan Mellstedt is working on:

--------------------------

Hakan Mellstedt

About
Tumor immunology with a focus on immunotherapy using monoclonal antibodies and cancer vaccines. The present research is addressing structural and functional characterization of ROR1 in hematological malignancies and solid tumors and the developement of therapeutic strategies using small molecules targeting the TK domain of ROR1 as well as monoclonal antibodies recognizing the extracellular part of ROR1. A future strategy will also include developement of active ROR1 specific immunotherapy

Following: 56

Followers: 122

https://www.researchgate.net/profile/Hakan_Mellstedt

This I think many will find interesting, and I wonder if Peregrine can scientifically prove with all their data that another advantage with combination Bavi is less damage to the kidneys.

--------------------

(taken from middle of pg 4084)

The kidneys are supposed to be the most sensitive organ to immune complexes. No patient had pro-teinuria or red blood cells in the urine, which are sensitive indicators of renal immune complexes depositions. Serum immune complexes were analyzed at each treatment cycle. No circulating immune complexes could
be detected.

http://www.bloodjournal.org/content/bloodjournal/84/12/4078.full.pdf?sso-checked=true

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109418488